World
Archived — This article has been archived. The information may be outdated.
Oxford tests first Bundibugyo Ebola vaccine dose
The Indian Practitioner··25 Jul
Oxford researchers administered the first human dose of an experimental vaccine against the Bundibugyo Ebola strain in a Phase one BD Ebov trial. Fifty healthy adults aged eighteen to fifty five will test safety and immune response. No licensed vaccine exists for this strain unlike approved Zaire Ebola shots. The ChAdOx1 platform supports the trial.
Prism
What It Means For You
- Bundibugyo Ebola outbreaks in Congo and Uganda currently lack approved vaccines or specific treatments.
- A successful Phase one result would still require larger efficacy studies before routine deployment.
- Ongoing outbreaks have killed more than one thousand people while conflict and misinformation complicate response efforts.
What's Happening
- University of Oxford started the BD Ebov Phase one trial for Bundibugyo Ebola on July 25 reporting.
- Researchers gave the first dose to a volunteer in the fifty participant safety and immunogenicity study.
- The vaccine uses Oxford's ChAdOx1 viral vector technology adapted for the Bundibugyo strain.
Filling Gap Beyond Zaire Ebola Shots
- Bundibugyo Ebola has caused multiple African outbreaks but lacked dedicated vaccine development until now.
- Scientists accelerated work to prepare for future outbreaks where Zaire focused vaccines would not protect.
- Health officials continue battling one of the largest recorded Bundibugyo outbreaks with over one thousand deaths.
all-newstop-stories
